Patent ID: 11903973
Assignee: VOR BIOPHARMA INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 0:
1. A method of treating a hematopoietic malignancy, comprising administering to a subject in need thereof:
(a) a plurality of genetically engineered hematopoietic cells (HCs) comprising:
(i) a genetically engineered gene encoding CD33 that is engineered to have reduced or eliminated expression of CD33, and
(ii) a genetically engineered gene encoding CD123 that is engineered to have reduced or eliminated expression of CD123; and

(b) a therapeutically effective amount of at least one agent comprising an anti-CD33 binding domain or an anti-CD123 binding domain;
wherein the hematopoietic malignancy is acute myeloid leukemia (AML).